# Patent

## Title
Antibody to macrophage-derived inflammatory mediator (MIP-1.alpha. and

## Abstract

An anti-FHV-1 recombinant antibody efficacious for treatment, prevention and diagnosis of feline herpes virus-1 (FHV-1) and a gene fragment useful for preparing the same are provided. A cell producing a mouse monoclonal antibody having an excellent neutralizing activity against FHV-1 was constructed, and a gene fragment coding for V region of said antibody responsible for the specific binding activity against FHV-1 was obtained. Using this gene fragment and a gene fragment coding for the constant region of a feline antibody, a chimeric anti-FHV-1 recombinant antibody is obtained.

## Background
This is a 371 national stage application of PCT/JP93/01724, filed Nov. 25, 1993.

The present invention relates to a novel feline monoclonal antibody usable for diagnosis, treatment and prevention of feline herpes virus-1 (FHV-1) infection. More particularly, it relates to a felinized anti-FHV-1 recombinant antibody wherein a constant region of a mouse-type anti-FHV-1 neutralizing monoclonal antibody is replaced with a feline antibody constant region, and a gene fragment encoding said antibody.

A cat is such an animal that has been loved by humans as a pet from ancient times and, in modern times, called as Companion species, is becoming a member of a human society. On the other hand, a cat has hitherto greatly contributed to humans as an experimental animal in various fields such as medicine, pharmaceutics, animal husbandry veterinary and psychology, and in recent years, the contribution of a cat has further increased to be used as an SPF Cat in an effectiveness assay or safety test for drugs. In any case, as a matter of course, more reliable knowledge on feline diseases, especially on infectious diseases, is increasingly needed and the establishment of a method for diagnosis, treatment and prevention of these diseases is required.

Many viral diseases of cats have been known. Among them, an upper tracheal disease caused by FHV-1 is acute and shows a high lethality. For both diseases, there is no specific treating drug and only a symptomatic treatment for preventing a secondary infection by the use of antibiotics, sulfonamide drugs, etc., and hence, there remains a problem in a conventional method for treatment.

Hitherto, a hiperimmune serum or a serum-derived immunoglobulin have been used as a medicament for treatment of viral diseases and have shown satisfactory results. Nowadays, however, feline serum materials are hardly available due to promotion of Be-Kind-to-Animals thought, and hence, we are in a situation that this treating method cannot be used in spite of desire to use this method. Accordingly, in place of the conventional hiperimmune serum, a monoclonal antibody capable of neutralizing FHV-1 will possibly greatly contribute to the treatment of FHV-1 infection.

There have been established several neutralizing monoclonal antibodies against FHV-1. However, all the monoclonal antibodies established hitherto are antibodies derived from a mouse hybridoma. When these antibodies are administered to a cat as a medicament, since they are a heterogeneous protein, they will show weaker binding capacity to complement or immunocompetent cells having an Fc receptor present in blood than that of homo species (cat) and appear to hardly induce cell damage by "antibody+complement" or antibody-dependent cellular cytotoxicity, cell-mediated cell damage. It is known that, in addition to the action by an antibody alone, these two immune reactions are also important for prevention of FHV-1 infection and for neutralization of virus (Horimoto T. et al., Jpn. J. Vet. Sci. 51, p1025, 1989). Therefore, it is possible that the conventional mouse antibodies cannot exhibit efficacious results in treatment.

Furthermore, it is also possible that the mouse antibodies recognized as a heterogeneous protein cause a side effect such as anaphylaxic shock or serum disease or show a shortened half-life, resulting in a decreased efficacy in treatment. Accordingly, when administered, the conventional mouse monoclonal antibodies have never been satisfactory but a felinized monoclonal antibody should have been used.

Under the circumstances, the present inventors have established a mouse monoclonal antibody, JH2, which neutralizes FHV-1 viral strain, have identified a nucleotide sequence of a gene encoding a variable region (V region) of said antibody, and have found a specific amino acid sequence in V region of said antibody which is deeply involved in the neutralization of FHV-1. Then, in order to felinize this mouse type monoclonal antibody, the present inventors have constructed a vector expressing an anti-FHV-1 chimeric antibody having an FHV-1 neutralizing activity by ligating the antibody V region gene coding for the anti-FHV-1 neutralizing antibody with a gene fragment coding for a constant region of feline antibody which the present inventors have previously found, have expressed said vector, and have successfully obtained the anti-FHV-1 chimeric antibody. That is, an object of the present invention is to provide an anti-FHV-1 felinized chimeric antibody which has hitherto never been reported and is prepared by utilizing a genetic engineering technique by replacing the constant region of the mouse-type antibody with a constant region of a feline antibody, and to provide a gene fragment coding for said antibody useful for production of the same. Thus, now it becomes possible to apply an anti-FHV-1 antibody as diagnostic, treating and preventing agents which is effective against FHV-1 infection without side effects.

FIG. 1 illustrates results of agarose gel electrophoresis of VH, V.kappa. genes of the anti-FHV-1 antibody JH2 amplified by PCR.

FIG. 2 shows a base sequence (SEQ ID NO:1) of a VH gene obtained in Example (3) and an amino acid sequence (SEQ ID NO:2) encoded by said gene.

FIG. 3 shows a base sequence (SEQ ID NO:3) of a V.kappa. gene obtained in Example (4) and an amino acid sequence (SEQ ID NO:4) encoded by said gene.

FIG. 4 shows results of homologous comparison of the VH region between JH2 (SEQ ID NO:2) and other antibodies (SEQ ID NOS:14-17) at an amino acid level.

FIG. 5 shows results of homologous comparison of the V.kappa. region between JH2 (SEQ ID NO:4) and other antibodies (SEQ ID NOS:18-21) at an amino acid level.

FIG. 6 shows a restriction enzyme map of a vector expressing an H chain of anti-FHV-1 chimeric antibody.

FIG. 7 shows a restriction enzyme map of a vector expressing an L chain of anti-FHV-1 chimeric antibody.

FIG. 8 shows a reactivity of the chimeric antibody of the present invention with an anti-feline antibody.

FIG. 9 is an illustration showing results of SDS-PAGE of the chimeric antibody of the present invention.

FIG. 10 shows a binding of the chimeric antibody of the present invention to FHV-1.

FIG. 11 shows effectiveness of the chimeric antibody of the present invention for cats compulsorily infected with FHV-1 K1 strain.

FIG. 12 shows effectiveness of the chimeric antibody of the present invention for SPF cats compulsorily infected with FHV-1 K1 strain.

First, the present inventors have conducted a cell fusion between a lymphocyte of mice immunized with FHV-1-K1 viral particles and a mouse myeloma cell in accordance with the conventional manner to prepare a hybridoma. As a result of cloning with an index of viral neutralizing activity in culture supernatant of hybridomas, the present inventors have successfully established an antibody-producing cell, JH2, which produces a monoclonal antibody being quite excellent in FHV-1 neutralizing activity.

It is generally known that a specificity of an antibody against an antigen is based on amino acids in a variable (V) region of an antibody. Thus, the present inventors have studied what amino acids constitute V region of JH2. The amino acid sequence was determined by cloning a gene coding for V region of said antibody and studying a nucleotide sequence thereof.

As a result, V region was found to have the amino acid sequence as shown in FIGS. 3 and 4. Generally, there exist about 200 VH, about several 10s D, and 4 JH genes in an H chain gene region of an antibody. On the other hand, there are about 200 V.kappa., and 4 J.kappa. genes in an L(.kappa.) chain gene region. It is known that, with differentiation of B cells, each one gene is selected from these V(D)J gene fragments and rearranged to form a gene coding for an amino acid of a whole variable region. Addition of N sequence and a Somatic Mutation give a great number of varieties of an antibody variable region. The variable region gene of JH2 of the present invention is a unique one selected among such varieties. CDR shown in Figures is an important region for binding with an antigen. Also in case of JH2, it appears that the amino acid of these six CDR regions binds with FHV to induce a neutralizing reaction. Especially, "Asp Gly Ala Trp Phe Pro Phe" (corresponding to amino acid residues 126 to 132 of SEQ ID NO:2) in H chain CDR3 was found to be an unique amino acid sequence by a homologous comparison with variable regions of another antibodies.

Accordingly, the amino acids of H chain CDR3 as well as another CDR regions of H and L chains are considered to be closely related to binding and neutralizing reactions with FHV-1. This has been firstly revealed by isolating the variable region gene of JH2 antibody. Determination of a nucleotide sequence and an amino acid sequence of JH2 antibody further enables, based on these sequences, enhancement of an antigen-binding activity and felinization of V region itself. An antibody or a peptide having such amino acid sequence is conjectured to be usable for treatment, diagnosis and prevention of FHV-1 infection.

That is, the gene fragment coding for V region of the antibody having a neutralizing activity against FHV-1 as provided according to the present invention is a gene fragment having the following characteristics.

A gene fragment coding for VH or a part thereof of the antibody which specifically reacts with feline herpes virus-1 (FHV-1) is a gene fragment of VH of the antibody wherein the nucleotide sequence coding for CDR3 of said antibody is a nucleotide sequence coding for the following amino acid sequence: NO:2).

A preferable gene fragment of VH having a nucleotide sequence coding for such sequence includes a gene fragment wherein nucleotide sequences coding for CDRs 1 to 3 of said antibody are nucleotide sequences each coding for the following amino acid sequences: 86 of SEQ ID NO:2) SEQ ID NO:2)

Furthermore, by way of example, a preferable sequence of the above VH gene fragment includes a nucleotide sequence coding for the amino acid sequence as described in Sequence Listing: SEQ ID NO:2. A specific nucleotide sequence includes, for example, the nucleotide sequence corresponding to nucleotides 21 to 449 of SEQ ID NO:1.

On the other hand, a gene fragment coding for VL or a part thereof of the antibody which specifically reacts with feline herpes virus-1 (FHV-1) includes a gene fragment wherein nucleotide sequences coding for CDRs 1 to 3 of said antibody are nucleotide sequences each coding for the following amino acid sequences: NO:4)

Furthermore, by way of example, a preferable sequence of the above VL gene fragment includes a nucleotide sequence coding for the amino acid sequence as described in Sequence Listing: SEQ ID NO:4. A specific nucleotide sequence includes, for example, the nucleotide sequence corresponding to nucleotides 23 to 403 of SEQ ID NO:3.

In the meanwhile, it appears to be difficult to administer directly to cats the mouse-type antibody JH2 for treatment of FHV-1 infection in view of reduction of efficacy, side effects, shortened half-life, etc. This is because the antibody itself is a protein heterogeneous to cats derived from mice, and hence, one can foresee that said antibody cannot possibly bind to a complement or immunocompetent cells having Fc receptor of cats, and as a result, ADCC or CDC is hardly inducible. As mentioned above, considering that these activities greatly contribute to the viral neutralization in FHV infection, the antibody needs to have an Fc region derived from cats.

Furthermore, if the antibody exhibits immunogenicity as a heterogenous protein within the living body, it is possibly cleared away quickly from the living body to shorten the half-life or it may provoke side effects such as a serum disease. It is said that the immunogenicity of an antibody molecule is localized in the Fc region. In this sense, the Fc region preferably has an amino acid sequence of an antibody molecule derived from cats as a homogenous protein.

Now, the present inventors have successfully prepared a felinized JH2 by replacing the antibody constant region of JH2 with that derived from cats utilizing a genetic engineering technique.

Such felinized antibody, i.e. anti-FHV-1 chimeric antibody, can be prepared by ligating the feline antibody constant region gene; CH gene and CL gene to the downstream (3' site) of the above-mentioned gene coding for VH of anti-FHV-1 antibody and the VL gene provided by the present invention to construct a structural gene of antibody H chain and L chain coding for said felinized antibody, i.e. felinized chimeric antibody, and expressing said structural gene in a suitable animal cell, etc.

The gene coding for such feline antibody constant region has previously been found by the present inventors (Japanese Patent First Publication No. 3-123488, Japanese Patent First Publication No. 3-201986 and Japanese Patent First Publication No. 3-72873). A nucleotide sequence of the gene coding for such feline antibody constant region includes, as a gene fragment coding for CH, that of a gene fragment coding for the amino acid sequence as described in Sequence Listing: SEQ ID NO:6. A specific nucleotide sequence of said gene includes the nucleotide sequence as described in Sequence Listing: SEQ ID NO:5. As a gene coding for C.kappa., a nucleotide sequence of said gene includes that of a gene fragment coding for the amino acid sequence as described in Sequence Listing: SEQ ID NO:8. A specific nucleotide sequence of said gene includes the nucleotide sequence as described in Sequence Listing: SEQ ID NO:7. As a gene coding for C.lambda., a nucleotide sequence of said gene includes that of a gene fragment coding for the amino acid sequence as described in Sequence Listing: SEQ ID NO:10. A specific nucleotide sequence of said gene includes the nucleotide sequence as described in Sequence Listing: SEQ ID NO:9.

The gene fragment coding for V region of the antibody having a neutralizing activity against FHV-1 of the present invention, in addition to the production of the chimeric antibody comprising the mouse-derived V region and the cat-derived C region as mentioned above, can also be used for preparing a reshaped antibody in which a frame (FR) region of V region is also replaced with that derived from an antibody of animals other than mice (in case of the present invention, derived from a feline antibody). There has not yet been totally reported an amino acid sequence of a general V region FR region of a feline antibody. However, a part of such sequence has already been reported (KEHO J. M. et al., Proc. N.A.S. 69, p2052, 1972). Based on these and the amino acid sequence of the constant region of feline antibody which the present inventors have previously found etc., it will be possible to prepare a suitable primer, to clone a gene coding for a feline antibody V region and to determine an amino acid sequence of said FR region. A reshaped antibody can be prepared basically in accordance with the known technique (for example, Japanese Patent First Publication No. 62-296890). The gene fragment of the present invention used in this case is referred to, as a part of a gene coding for VH chain and VL chain, a gene fragment containing at least a nucleotide sequence coding for the following amino acid sequence: NO:2).

Preferably, nucleic acids coding for CDRs in V region of said reshaped antibody are those coding for the following amino acid sequences for VH chain and VL chain, respectively:

VH chain: 86 of SEQ ID NO:2) SEQ ID NO:2)

VL chain: NO:4)

In addition, the present inventors have further found previously that, in preparing the reshaped antibody as mentioned above, an antibody having an excellent specificity of the original mouse monoclonal antibody can sometimes be prepared by replacing a portion of FR region of V region adjacent to CDRs with that derived from mice in addition to replacement of CDRs in V region with those derived from mice rather than replacement of CDRs alone in V region with those derived from mice in accordance with the conventional technique. That is, by replacing a portion of FR region of V region as well with that derived from mice by reference to the amino acid sequence described in FIG. 2 for VH chain and the amino acid sequence described in FIG. 3 for VL chain, a reshaped antibody can possibly be prepared which is more excellent than the reshaped antibody in which only CDRs are replaced with those derived from mice.

As mentioned above, the structural gene coding for the felinized anti-FHV-1 recombinant antibody (so called chimeric antibody) is prepared by constructing a V region structural gene for a chimeric antibody or a reshaped antibody by the use of the gene coding for the variable region of the anti-FHV-1 antibody of the present invention and ligating this structural gene with the gene coding for the constant region of feline antibody which the present inventors have previously found. The recombinant antibody of the present invention obtained by ligating this structural gene to the downstream of a suitable promotor gene and expressing the resultant in an animal cell, etc. in accordance with the known technique retained an excellent neutralizing activity like the mouse-type antibody JH2. When administered to FHV-infected cats, the recombinant antibody of the present invention alleviated the disease state without any significant side effect. E. A. Emini et al. have studied a preventive effect of a monoclonal antibody against HIV infection in chimpanzee. As a result, it was found that a humanized chimeric antibody could prevent HIV infection (E. A. Emini et al., Nature, 355, p728, 1992) but the original mouse-type antibody could not (E. A. Emini et al., J. Virol., 64, p3674, 1990). It appears that this is because the latter could not induce Fc region-dependent ADCC or CDC activities and showed a shortened half-life.

As for the effectiveness of FH2 antibody in FHV-infected cats found by the present inventors this time, it appears that the mouse-type antibody has a weak effect but the effect can be exerted only by the felinized antibody like the above-mentioned previous case.

From the above-mentioned point of view, the anti-FHV-1 chimeric antibody FH2 of the present invention can be a substantial medicament for treatment and prevention of FHV-1 infection.

The present invention is explained in more detail hereinbelow by means of Example.

(1) Production of hybridoma producing anti-FHV-1 neutralizing monoclonal antibody

A culture supernatant of FL cells (feline lung cells) infected with FHV-1 was precipitated with ammonium sulfate. After dialysis, the precipitate was resuspended in a phosphate buffer and administered peritoneally to BALB/c mouse for immunization together with Freund's complete adjuvant. After two weeks, mouse lymphocytes and mouse myeloma cells (P3U1) were cell-fused by the polyethylene glycol method to prepare hybridomas. Cloning was conducted by an index of a viral neutralizing activity of culture supernatant of hybridomas and thereby four kinds of FHV-1 neutralizing monoclonal antibody producing cells were established. The following Table 1 shows a minimum effective concentration of each monoclonal antibody necessary for neutralizing 10 TCID.sub.50 of FHV-1. Among these monoclonal antibodies, JH2 antibody most strongly neutralized FHV-1-K1 strain. ______________________________________ Minimum effective concentration Name of antibody Class   for neutralization (.mu.g/ml ______________________________________ JH2        .gamma.1, .kappa. 0.39 JH3        .gamma.1, .kappa. 6.3 JH4        .gamma.1, .kappa. 100 JH7        .gamma.2a, .kappa. 6.3 ______________________________________

(2) Isolation of variable region gene of anti-FHV-1 antibody (JH2)

Whole RNAs were extracted from 1 to 0.5.times.10.sup.7 cells (hybridomas) and mRNAs were purified with Oligo dT column (manufactured by Stratagene, Poly(A) Quick mRNA Purification Kit). A single-stranded cDNA was synthesized with reverse transcriptase (Takara; all reagents used for genetic engineering were those manufactured by Takara unless otherwise mentioned).

Oligonucleotides having a base sequence at the leader region (MHL34, MKL104) as a 5' primer and those having a base sequence at the J region (MHJ3, MKJ124) as a 3' primer were synthesized. The base sequence of these primers are shown hereinbelow.

Primer for amplification of VH chain SEQ ID NO:1)

Primer for amplification of VK chain

To 20 ng of cDNA were added each 50 pmol of primers. PCR (Polymerase Chain Reaction) was conducted for 30 cycles, each cycle comprising 94.degree. C. for 1 minute, 55.degree. C. for 1 minute and 72.degree. C. for 1 minute, to amplify the variable region gene (VH, V.kappa.) flanked by both primers. FIG. 1 shows an agarose electro-phoresis pattern of the amplified gene fragments. A size of VH (H chain) and V.kappa. (L chain) genes were about 400 bp and about 400 bp, respectively, and virtually corresponded to the bands as expected.

(3) Determination of base sequence

A base sequence of each gene fragment amplified in 1 was determined by the dideoxy method. Each of VH and V.kappa. gene fragments was cloned into pUC18 and a base sequence thereof was determined by the dideoxy method (manufactured by USB, Sequenase ver. 2).

FIG. 2 shows a base sequence of VH gene of JH2 antibody and an amino acid sequence coded by said gene. This gene took an open reading frame (ORF) and preserved Cys for forming a domain structure, and hence, was found to be suitable for expression. It was also found that rearrangement occurred at JH3. Then, a homology reference was conducted for the amino acid sequence coded by this gene. Using GENETYX-CD (Software) as a reference software, a data base of Gene Bank was referenced. As a result, antibodies 1 to 5 belonging to VHIII/J606 family were found to have highly homologous VH (FIG. 4). In FIG. 4, the mark (*) shows an amino acid homologous to that of other VHs and the region other than this mark represents an amino acid sequence found only in JH2. Especially, the underlined portion represents a novel amino acid sequence which has hitherto never been reported and is characteristic region of JH2 antibody.

FIG. 3 shows a base sequence of V.kappa. gene of JH2 antibody and an amino acid sequence coded by said gene. Like in case of H chain, this gene took ORF and preserved Cys for forming a domain structure, and hence, was found to be suitable for expression. It was also found that rearrangement occurred at J.kappa.1. FIG. 5 shows a result of a homology reference. V.kappa. of JH2 also showed homology with other V.kappa..

That is, it appeared that the underlined portion in VH chain is specific for JH2 antibody and is an important amino acid sequence responsible for an antigen binding activity.

(4) Preparation of anti-FHV-1 chimeric antibody genes

The variable region genes amplified by PCR were ligated to the gene coding for .gamma. chain constant region of feline antibody CB25.gamma. (Japanese Patent First Publication No. 3-201986) or to the gene coding for .kappa. chain constant region of feline antibody CEK (Japanese Patent First Publication No. 3-123488). There were used the chicken .beta.-actin promoter (Japanese Patent Application No. 1-309785) as an expression promoter and neo (Southern P. J. J. Mol. Appl. Genet., 1, 327, 1982) or dhfr gene (Stark, G. R. and Wahl, G. M., Annu. Rev. Biochem., 53, p447, 1984) as a selection marker. FIG. 6 and FIG. 7 show restriction enzyme maps of the chimeric antibody H chain and L chain expression vectors prepared, respectively.

(5) Preparation of stable tranformant

Each 10 .mu.g of the gene coding for the chimeric antibody H chain and L(.kappa.) chain as shown in FIG. 6 and FIG. 7 were digested with PvuI and 2.times.10.sup.6 mouse myeloma cells P3-X63-Ag8-6.5.3 (ATCC CRL1580) were co-transfected with the digested products by using lipofectin (manufactured by BRL). The transfected cells were cultured in 5% FCS/RPMI1640 selection medium containing 0.25.times.10.sup.-7 M methotrexate (MTX) to select drug-resistant strains (transformant).

Chimeric antibody producing cells were cloned by a limiting dilution method with an index of feline IgG expressed in culture supernatant to establish an expression cell, FH2. The properties of this cell were analyzed as follows.

(6) Reaction with anti-feline antibody

Culture supernatants of FH2 (chimeric antibody expressing cell) and of JH2 (mouse monoclonal antibody expressing cell) were added to a microtiter plate immobilized with an anti-feline antibody (E.Y.LABS.INC) and the reaction was conducted at room temperature for 1 hour. After washing the plate, HRP-anti-feline antibody (E.Y.LABS.INC) was reacted at room temperature for 1 hour. After washing the plate again, color was developed with TMBZ and an absorbance at 450 nm was measured to analyze the reactivity with the anti-feline antibody (FIG. 8).

The culture supernatant of FH2 reacted with the anti-feline antibody in a concentration-dependent manner whereas the culture supernatant of JH2 which expresses the mouse antibody did not react with the anti-feline antibody. This revealed that the chimeric antibody expressed by FH2 cells is a feline antibody.

(7) Identification of chimeric antibody by SDS-PAGE

The chimeric antibody was purified from the culture supernatant with Protein A (manufactured by Bio Rad, MAPS-II). The purified chimeric antibody was subjected to 12.5% SDS-PAGE and compared with a feline IgG sample (polyclonal antibody). A molecular weight of the purified antibody was determined with a prestained marker manufactured by Bio Rad.

As shown in FIG. 9, the chimeric antibody detected bands at 5.times.10.sup.4 for H chain and at 2.5.times.10.sup.4 for L chain under reduced conditions and a band at around 1.5.times.10.sup.5 under non-reduced conditions. This revealed that H and L chains form a dimer of H2L2 which has the same form as that of IgG present in the cat body.

(8) Reaction with FHV-1 viral particle

Then, an antigen binding activity of the chimeric antibody was studied. The culture supernatant (from FH2 and JH2) was added to a microtiter plate immobilized with FHV-1-K1 (crude product by the ammonium sulfate precipitation). After washing the plate, it was reacted with either HRP-anti-feline antibody or HRP-anti-mouse antibody. Color was developed with TMBZ and the reactivity with FHV-1 viral particle was studied. Like the mouse antibody JH2, FH2 antibody specifically reacted with FHV-1-K1. However, the recombinant chimeric antibodies specific for another viruses (antibodies having the same feline constant region and different mouse variable regions) did not reacted (FIG. 10).

(9) Neutralization test against FHV-1 virus

Then, the neutralization activity against FHV-1 of the chimeric antibody was studied. The culture supernatant (from FH2 and JH2) was reacted with 100 TCID.sub.50 of FHV-1 virus at 4.degree. C. for 6 hours. Thereto were added 0.25.times.10.sup.5 CRFK cells and cultured at 37.degree. C. for 2 days. CPE (Cell Rounding) was observed and a minimum effective concentration for neutralization was determined.

The results are summarized in the following Table 2. As a result, it was confirmed that FH2 antibody neutralizes FHV-1 at 1.95 .mu.g/ml. ______________________________________ Minimum Effective Concentration for Antibody       Neutralization (.mu.g/ml) ______________________________________ Chimeric antibody (FH2) 1.95 Mouse antibody (JH2) 1.25 ______________________________________

(10) Effectiveness and safety of FH2 in cats compulsorily infected with FHV

Cats weighing 1.5 to 3.0 Kg were compulsorily infected with 10.sup.4 TCID.sub.50 of FHV-1-K1 strain through nose. At the second day, 30 and 10 mg/Kg of FH2 was administered via the jugular vein. General clinical conditions such as weight, temperature, an amount of taking meals, an amount of drinking water and spirits, and respiratory lesions such as tears, conjunctivitis, rhinorrhea, sneeze and cough were observed with the lapse of time and scored as 0 for no symptom, 1 for light symptom, 2 for moderate symptom and 3 for severe symptom. As a result, both groups administered with 10 and 30 mg/kg alleviated the symptoms (FIG. 11). Then, SPF cats weighing 1.4 to 2.3 kg were compulsorily infected with 10.sup.4 TCID.sub.50 of FHV-1-K1 strain. At the second day, 30 and 10 mg/kg of FH2 were administered via the jugular vein and the clinical conditions were observed. As a result, the onset of the symptoms were inhibited in the group administered with FH2 (FIG. 12). These showed the in vivo usefulness of FH2 against FHV infection.

In addition, after administration of FH2, no side effect such as diarrhea, vomiting or another shock-like symptom was observed, and hence, the safety of FH2 was confirmed.

From the above-mentioned point of view, FH2 antibody can be applied as diagnostic, treating and preventing agents effective against FHV-1 infection with no side effect.

Industrial Applicability of the Invention

The feline monoclonal antibody of the present invention is effective against feline virus herpes virus-1 infection and is applicable as diagnostic, treating and preventing agents against said disease. SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 21 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 462 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 21..449 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: TCTAGAAGCTTGCCGCCACCATGGGCAGACTTACATTCTCATTCCTGCTA50 MetGlyArgLeuThrPheSerPheLeuLeu 1510 CTGATTGTCCCTGCATATGTCCTGTCCCAGGTTACTCTGAAAGAGTCT98 LeuIleValProAlaTyrValLeuSerGlnValThrLeuLysGluSer 152025 GGCCCTGGGATATTGCAGCCCTCCCAGACCCTCAGTCTGACTTGTTCT146 GlyProGlyIleLeuGlnProSerGlnThrLeuSerLeuThrCysSer 303540 TTCTCTGGGTTTTCACTGAGCACTTCTGGTATGGGTGCAGGCTGGATT194 PheSerGlyPheSerLeuSerThrSerGlyMetGlyAlaGlyTrpIle 455055 CGTCAGCCATCAGGGAAGGGTCTGGAGTGGCTGGCACACATTTGGTGG242 ArgGlnProSerGlyLysGlyLeuGluTrpLeuAlaHisIleTrpTrp 606570 GATGATGTCAAGCGCTATAACCCAGCCCTGAAGAGCCGACTGACTATC290 AspAspValLysArgTyrAsnProAlaLeuLysSerArgLeuThrIle 75808590 TCCAAGGATACCTCCAGCAGCCAGGTATTCCTCAAGATCGCCAGCGTG338 SerLysAspThrSerSerSerGlnValPheLeuLysIleAlaSerVal 95100105 GACACTGCAGATACTGCCACATATTTTTGTGTTCGATCCCAGATCTAC386 AspThrAlaAspThrAlaThrTyrPheCysValArgSerGlnIleTyr 110115120 TTTGATTACGACGGGGCCTGGTTTCCTTTCTGGGGCCAAGGGACTCTG434 PheAspTyrAspGlyAlaTrpPheProPheTrpGlyGlnGlyThrLeu 125130135 GTCACTGTCTCTGCAGGTGAGTGGATCC462 ValThrValSerAla 140 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 143 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: MetGlyArgLeuThrPheSerPheLeuLeuLeuIleValProAlaTyr 151015 ValLeuSerGlnValThrLeuLysGluSerGlyProGlyIleLeuGln 202530 ProSerGlnThrLeuSerLeuThrCysSerPheSerGlyPheSerLeu 354045 SerThrSerGlyMetGlyAlaGlyTrpIleArgGlnProSerGlyLys 505560 GlyLeuGluTrpLeuAlaHisIleTrpTrpAspAspValLysArgTyr 65707580 AsnProAlaLeuLysSerArgLeuThrIleSerLysAspThrSerSer 859095 SerGlnValPheLeuLysIleAlaSerValAspThrAlaAspThrAla 100105110 ThrTyrPheCysValArgSerGlnIleTyrPheAspTyrAspGlyAla 115120125 TrpPheProPheTrpGlyGlnGlyThrLeuValThrValSerAla 130135140 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 424 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 23..403 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GGAATTCAAGCTTGCCGCCACCATGGTATCCTCACCTCAGTTCCTTGGACTT52 MetValSerSerProGlnPheLeuGlyLeu 145150 ATGCTTTTTTGGATTTCAGCCTCCAGAGGTGATATTGTGCTAACTCAG100 MetLeuPheTrpIleSerAlaSerArgGlyAspIleValLeuThrGln 155160165 TCTCCAGCCACCCTGTCTGTGACTCCAGGAGATAGCGTCAGTCTTTCC148 SerProAlaThrLeuSerValThrProGlyAspSerValSerLeuSer 170175180185 TGCAGGGCCAGCCAAAGTATTAGCAACAACCTACACTGGTATCAACAA196 CysArgAlaSerGlnSerIleSerAsnAsnLeuHisTrpTyrGlnGln 190195200 AAATCACATGAGTCTCCAAGGCTTCTCATCAAGTATGCTTCCCAGTCC244 LysSerHisGluSerProArgLeuLeuIleLysTyrAlaSerGlnSer 205210215 ATCTCTGGGATCCCCTCCAGGTTCAGTGGCAGTGGATCAGGGACAGAT292 IleSerGlyIleProSerArgPheSerGlySerGlySerGlyThrAsp 220225230 TTCACTCTCAGTATCAACAGTGTGGAGACTGAAGATTTTGGAATGTAT340 PheThrLeuSerIleAsnSerValGluThrGluAspPheGlyMetTyr 235240245 TTCTGTCAACAGAGTAACAGCTGGCCTCACACGTTCGGTGCTGGGACC388 PheCysGlnGlnSerAsnSerTrpProHisThrPheGlyAlaGlyThr 250255260265 AAGCTGGAGCTGAAACGTAAGTGGATCCAGATCTAG424 LysLeuGluLeuLys 270 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 127 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: MetValSerSerProGlnPheLeuGlyLeuMetLeuPheTrpIleSer 151015 AlaSerArgGlyAspIleValLeuThrGlnSerProAlaThrLeuSer 202530 ValThrProGlyAspSerValSerLeuSerCysArgAlaSerGlnSer 354045 IleSerAsnAsnLeuHisTrpTyrGlnGlnLysSerHisGluSerPro 505560 ArgLeuLeuIleLysTyrAlaSerGlnSerIleSerGlyIleProSer 65707580 ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsn 859095 SerValGluThrGluAspPheGlyMetTyrPheCysGlnGlnSerAsn 100105110 SerTrpProHisThrPheGlyAlaGlyThrLysLeuGluLeuLys 115120125 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1005 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..999 (D) OTHER INFORMATION: /function="ok1" /product= "k6" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ACCACGGCCCCATCGGTGTTCCCACTGGCCCCCAGCTGCGGGACCACA48 ThrThrAlaProSerValPheProLeuAlaProSerCysGlyThrThr 130135140 TCTGGCGCCACCGTGGCCCTGGCCTGCCTGGTGTTAGGCTACTTCCCT96 SerGlyAlaThrValAlaLeuAlaCysLeuValLeuGlyTyrPhePro 145150155 GAGCCGGTGACCGTGTCCTGGAACTCCGGCGCCCTGACCAGCGGTGTG144 GluProValThrValSerTrpAsnSerGlyAlaLeuThrSerGlyVal 160165170175 CACACCTTCCCGGCCGTCCTGCAGGCCTCGGGGCTGTACTCTCTCAGC192 HisThrPheProAlaValLeuGlnAlaSerGlyLeuTyrSerLeuSer 180185190 AGCATGGTGACAGTGCCCTCCAGCAGGTGGCTCAGTGACACCTTCACC240 SerMetValThrValProSerSerArgTrpLeuSerAspThrPheThr 195200205 TGCAACGTGGCCCACCCGCCCAGCAACACCAAGGTGGACAAGACCGTG288 CysAsnValAlaHisProProSerAsnThrLysValAspLysThrVal 210215220 CGCAAAACAGACCACCCACCGGGACCCAAACCCTGCGACTGTCCCAAA336 ArgLysThrAspHisProProGlyProLysProCysAspCysProLys 225230235 TGCCCACCCCCTGAGATGCTTGGAGGACCGTCCATCTTCATCTTCCCC384 CysProProProGluMetLeuGlyGlyProSerIlePheIlePhePro 240245250255 CCAAAACCCAAGGACACCCTCTCGATTTCCCGGACGCCCGAGGTCACA432 ProLysProLysAspThrLeuSerIleSerArgThrProGluValThr 260265270 TGCTTGGTGGTGGACTTGGGCCCAGATGACTCCGATGTCCAGATCACA480 CysLeuValValAspLeuGlyProAspAspSerAspValGlnIleThr 275280285 TGGTTTGTGGATAACACCCAGGTGTACACAGCCAAGACGAGTCCGCGT528 TrpPheValAspAsnThrGlnValTyrThrAlaLysThrSerProArg 290295300 GAGGAGCAGTTCAACAGCACCTACCGTGTGGTCAGTGTCCTCCCCATC576 GluGluGlnPheAsnSerThrTyrArgValValSerValLeuProIle 305310315 CTACACCAGGACTGGCTCAAGGGGAAGGAGTTCAAGTGCAAGGTCAAC624 LeuHisGlnAspTrpLeuLysGlyLysGluPheLysCysLysValAsn 320325330335 AGCAAATCCCTCCCCTCCCCCATCGAGAGGACCATCTCCAAGGCCAAA672 SerLysSerLeuProSerProIleGluArgThrIleSerLysAlaLys 340345350 GGACAGCCCCACGAGCCCCAGGTGTACGTCCTGCCTCCAGCCCAGGAG720 GlyGlnProHisGluProGlnValTyrValLeuProProAlaGlnGlu 355360365 GAGCTCAGCAGGAACAAAGTCAGTGTGACCTGCCTGATCAAAAGCTTC768 GluLeuSerArgAsnLysValSerValThrCysLeuIleLysSerPhe 370375380 CACCCGCCTGACATTGCCGTCGAGTGGGAGATCACCGGACAGCCGGAG816 HisProProAspIleAlaValGluTrpGluIleThrGlyGlnProGlu 385390395 CCAGAGAACAACTACCGGACGACCCCGCCCCAGCTGGACAGCGACGGG864 ProGluAsnAsnTyrArgThrThrProProGlnLeuAspSerAspGly 400405410415 ACCTACTTCGTGTACAGCAAGCTCTCGGTGGACAGGTCCCACTGGCAG912 ThrTyrPheValTyrSerLysLeuSerValAspArgSerHisTrpGln 420425430 AGGGGAAACACCTACACCTGCTCGGTGTCACACGAAGCTCTGCACAGC960 ArgGlyAsnThrTyrThrCysSerValSerHisGluAlaLeuHisSer 435440445 CACCACACACAGAAATCCCTCACCCAGTCTCCGGGTAAATGAGCA1005 HisHisThrGlnLysSerLeuThrGlnSerProGlyLys 450455460 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 333 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: ThrThrAlaProSerValPheProLeuAlaProSerCysGlyThrThr 151015 SerGlyAlaThrValAlaLeuAlaCysLeuValLeuGlyTyrPhePro 202530 GluProValThrValSerTrpAsnSerGlyAlaLeuThrSerGlyVal 354045 HisThrPheProAlaValLeuGlnAlaSerGlyLeuTyrSerLeuSer 505560 SerMetValThrValProSerSerArgTrpLeuSerAspThrPheThr 65707580 CysAsnValAlaHisProProSerAsnThrLysValAspLysThrVal 859095 ArgLysThrAspHisProProGlyProLysProCysAspCysProLys 100105110 CysProProProGluMetLeuGlyGlyProSerIlePheIlePhePro 115120125 ProLysProLysAspThrLeuSerIleSerArgThrProGluValThr 130135140 CysLeuValValAspLeuGlyProAspAspSerAspValGlnIleThr 145150155160 TrpPheValAspAsnThrGlnValTyrThrAlaLysThrSerProArg 165170175 GluGluGlnPheAsnSerThrTyrArgValValSerValLeuProIle 180185190 LeuHisGlnAspTrpLeuLysGlyLysGluPheLysCysLysValAsn 195200205 SerLysSerLeuProSerProIleGluArgThrIleSerLysAlaLys 210215220 GlyGlnProHisGluProGlnValTyrValLeuProProAlaGlnGlu 225230235240 GluLeuSerArgAsnLysValSerValThrCysLeuIleLysSerPhe 245250255 HisProProAspIleAlaValGluTrpGluIleThrGlyGlnProGlu 260265270 ProGluAsnAsnTyrArgThrThrProProGlnLeuAspSerAspGly 275280285 ThrTyrPheValTyrSerLysLeuSerValAspArgSerHisTrpGln 290295300 ArgGlyAsnThrTyrThrCysSerValSerHisGluAlaLeuHisSer 305310315320 HisHisThrGlnLysSerLeuThrGlnSerProGlyLys 325330 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..327 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: AGTGATGCTCAGCCATCTGTCTTTCTCTTCCAACCATCTCTGGACGAG48 SerAspAlaGlnProSerValPheLeuPheGlnProSerLeuAspGlu 335340345 TTACATACAGGAAGTGCCTCTATCGTGTGCATATTGAATGACTTCTAC96 LeuHisThrGlySerAlaSerIleValCysIleLeuAsnAspPheTyr 350355360365 CCCAAAGAGGTCAATGTCAAGTGGAAAGTGGATGGCGTAGTCCAAACA144 ProLysGluValAsnValLysTrpLysValAspGlyValValGlnThr 370375380 AAGGCATCCAAGGAGAGCACCACAGAGCAGAACAGCAAGGACAGCACC192 LysAlaSerLysGluSerThrThrGluGlnAsnSerLysAspSerThr 385390395 TACAGCCTCAGCAGCACCCTGACGATGTCCAGGACGGAGTACCAAAGT240 TyrSerLeuSerSerThrLeuThrMetSerArgThrGluTyrGlnSer 400405410 CATGAAAAGTTCTCCTGCGAGGTCACTCACAAGAGCCTGGCCTCCACC288 HisGluLysPheSerCysGluValThrHisLysSerLeuAlaSerThr 415420425 CTCGTCAAGAGCTTCAACAGGAGCGAGTGTCAGAGAGAGTAGCCTAGCA337 LeuValLysSerPheAsnArgSerGluCysGlnArgGlu 430435440 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 109 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: SerAspAlaGlnProSerValPheLeuPheGlnProSerLeuAspGlu 151015 LeuHisThrGlySerAlaSerIleValCysIleLeuAsnAspPheTyr 202530 ProLysGluValAsnValLysTrpLysValAspGlyValValGlnThr 354045 LysAlaSerLysGluSerThrThrGluGlnAsnSerLysAspSerThr 505560 TyrSerLeuSerSerThrLeuThrMetSerArgThrGluTyrGlnSer 65707580 HisGluLysPheSerCysGluValThrHisLysSerLeuAlaSerThr 859095 LeuValLysSerPheAsnArgSerGluCysGlnArgGlu 100105 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 318 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..315 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: CAGCCCAAGTCGGCCCCCTCGGTCACACTCTTCCCACCCTCCAGTGAG48 GlnProLysSerAlaProSerValThrLeuPheProProSerSerGlu 110115120125 GAGCTCAGCGCAAACAAGGCCACCCTGGTGTGTCTCGTCAGTGACTTC96 GluLeuSerAlaAsnLysAlaThrLeuValCysLeuValSerAspPhe 130135140 TACCCCAGCGGCTTGACGGTGGCCTGGAAGGAAGATGGCACCCCCATC144 TyrProSerGlyLeuThrValAlaTrpLysGluAspGlyThrProIle 145150155 ACCAAGGGCGTGGAGACCACCAAGCCCTCCAGACAGAGCAACAACAAG192 ThrLysGlyValGluThrThrLysProSerArgGlnSerAsnAsnLys 160165170 TACGCGGCCAGCAGCTACCTGAGCCTGTCACCGAACGAGTGGAAATCT240 TyrAlaAlaSerSerTyrLeuSerLeuSerProAsnGluTrpLysSer 175180185 CACAGCAGATACACCTGCCAGGTCACGCACGAGGGGAGCACTGTGGAG288 HisSerArgTyrThrCysGlnValThrHisGluGlySerThrValGlu 190195200205 AAGAGTGTGGTCCCTGCAGAGTGCCCTTAG318 LysSerValValProAlaGluCysPro 210 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 105 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: GlnProLysSerAlaProSerValThrLeuPheProProSerSerGlu 151015 GluLeuSerAlaAsnLysAlaThrLeuValCysLeuValSerAspPhe 202530 TyrProSerGlyLeuThrValAlaTrpLysGluAspGlyThrProIle 354045 ThrLysGlyValGluThrThrLysProSerArgGlnSerAsnAsnLys 505560 TyrAlaAlaSerSerTyrLeuSerLeuSerProAsnGluTrpLysSer 65707580 HisSerArgTyrThrCysGlnValThrHisGluGlySerThrValGlu 859095 LysSerValValProAlaGluCysPro 100105 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GAAGATCTGGATCCACTCACCTGCAGAGACAGTGA35 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: GGAATTCAAGCTTGCCGCCACCATGGTWTYCTCACCTCAG40 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: CTAGATCTGGATCCACTTACGTTTKATTTCCARCTT36 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 122 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: AspValGlnHisIleSerPheGlnValThrLeuLysGluSerGlyPro 151015 GlyIleLeuGlnProSerGlnThrLeuSerLeuThrCysSerPheSer 202530 GlyPheSerLeuSerThrSerGlyMetGlyValSerTrpIleArgGln 354045 ProSerGlyLysGlyLeuGluTrpLeuAlaHisIleTyrTrpAspAsp 505560 AspLysArgTyrAsnProSerLeuLysSerArgLeuThrIleSerLys 65707580 AspThrSerArgAsnGlnValPheLeuLysIleThrSerValAspThr 859095 AlaAspThrAlaThrTyrTyrCysAlaArgArgGluGlyGlyArgSer 100105110 TyrPheAspTyrTrpGlyGlnGlyThrThr 115120 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 108 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: ProGlyIleLeuGlnProSerGlnThrLeuSerLeuThrCysSerPhe 151015 SerGlyPheSerLeuSerThrSerGlyMetGlyValGlyTrpIleArg 202530 GlnProSerGlyLysGlyLeuGluTrpLeuAlaHisIleTrpTrpAsp 354045 AspAspLysArgTyrAsnProAlaLeuLysSerArgLeuThrIleSer 505560 LysAspThrSerSerAsnGlnValPheLeuLysIleAlaSerValAsp 65707580 ThrAlaAspThrSerThrTyrTyrCysAlaArgAspTrpAspTyrPhe 859095 AspTyrTrpGlyGlnGlyThrThrLeuThrValSer 100105 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 114 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: GlyIleLeuGlnProSerGlnThrLeuSerLeuThrCysSerPheSer 151015 GlyPheSerLeuSerThrSerGlyMetGlyValGlyTrpIleArgGln 202530 ProSerGlyLysGlyLeuGluTrpLeuAlaHisIleTrpTrpAspAsp 354045 AspLysArgTyrAsnProAlaLeuLysSerArgLeuThrIleSerLys 505560 AspThrSerSerAsnGlnValSerLeuLysIleAlaSerValAspThr 65707580 AlaAspThrAlaThrTyrTyrCysAlaArgThrTyrTyrTyrGlySer 859095 SerHisTrpTyrPheAspValTrpGlyAlaGlyThrThrValThrVal 100105110 SerSer (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 108 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: ProGlyIleLeuGlnProSerGlnThrLeuSerLeuThrCysSerPhe 151015 SerGlyPheSerLeuSerThrSerGlyMetGlySerTrpIleArgGln 202530 ProSerGlyLysGlyLeuGluTrpLeuAlaHisIleTyrTrpAspAsp 354045 AspLysArgTyrAsnProSerLeuLysSerArgLeuThrIleSerLys 505560 AspThrSerArgAsnGlnValPheLeuLysIleThrSerValAspThr 65707580 AlaAspThrAlaThrTyrTyrCysAlaArgSerTyrGlyAsnGlyAsp 859095 TyrTyrAlaMetAspTyrTrpGlyGlnGlyThrSer 100105 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 127 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: MetValPheThrProGlnIleLeuGlyLeuMetLeuPheTrpIleSer 151015 AlaSerArgGlyAspIleValLeuThrGlnSerProAlaThrLeuSer 202530 ValThrProArgAspSerValSerLeuSerCysArgAlaSerGlnSer 354045 IleSerAsnAsnLeuHisTrpTyrGlnGlnLysSerHisGluSerPro 505560 ArgLeuLeuIleLysTyrAlaSerGlnSerIleSerGlyIleProSer 65707580 ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsn 859095 SerValGluThrGluAspPheGlyMetTyrPheCysGlnGlnSerAsn 100105110 SerTrpProLeuThrPheGlyAlaGlyThrLysLeuGluLeuLys 115120125 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 100 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: AspIleValLeuThrGlnSerProAlaThrLeuSerValThrProGly 151015 AspSerValSerLeuSerCysArgAlaSerGlnSerIleSerAsnAsn 202530 LeuHisTrpTyrGlnGlnLysSerHisGluSerProArgLeuLeuIle 354045 LysTyrAlaSerGlnSerIleSerGlyIleProSerArgPheSerGly 505560 SerGlySerGlyThrAspPheThrLeuSerIleAsnSerValGluThr 65707580 GluAspPheGlyMetTyrPheCysGlnGlnSerAsnSerTrpProHis 859095 ThrPheGlySer 100 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 107 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: AspIleValLeuThrGlnSerProAlaThrLeuSerValThrProGly 151015 AsnSerValSerLeuSerCysArgAlaSerGlnSerIleGlyAsnAsn 202530 LeuHisTrpTyrGlnGlnLysSerHisGluSerProArgLeuLeuIle 354045 LysTyrAlaSerGlnSerIleSerGlyIleProSerArgPheSerGly 505560 SerGlySerGlyThrAspPheThrLeuSerIleAsnSerValGluThr 65707580 GluAspPheGlyMetTyrPheCysGlnGlnSerAsnSerTrpProTyr 859095 ThrPheGlyGlyGlyThrLysLeuGluIleLys 100105 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 103 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: IleValLeuThrGlnSerProAlaThrLeuSerValThrProGlyAsp 151015 SerValLeuSerCysArgAlaSerGlnSerIleSerAsnAsnLeuHis 202530 TrpTyrGlnGlnLysSerHisGluSerProArgLeuLeuIleAsnTyr 354045 AlaSerGlnSerIleSerIleProSerArgPheSerGlySerGlySer 505560 GlyThrAspPheThrLeuIleIleAsnAsnValGluThrGluAspPhe 65707580 GlyMetTyrPheCysGlnGlnSerAsnSerTrpProLeuThrPheAla 859095 AlaGlyThrLysLeuGluLeu 100 __________________________________________________________________________

## Claims

1. A felinized chimeric antibody having a heavy chain variable region (VH) and a light chain variable region (VL) obtained from a murine antibody, which specifically reacts with feline herpes virus-1 (FHV-1) and has a neutralizing activity against FHV-1, wherein the amino acid sequence of one of the complementarity determining regions (CDRs) of heavy chain variable region (VH) has the amino acid sequence Asp Gly Ala Trp Phe Pro Phe (corresponding to amino acid residues 126 to 132 of SEQ ID NO:2) and the amino acid sequences of the constant (C) regions of the heavy (H) and light (L) chains are those obtained from a feline antibody.

2. The antibody of claim 1 wherein the CDRs in said VH and VL regions have the following amino acid sequences: VH: SEQ ID NO:2; amino acids 71 to 86 of SEQ ID NO:2; acids 119 to 132 of SEQ ID NO:2; VL: 54 of SEQ ID NO:4; NO:4; and of SEQ ID NO:4.

3. The antibody of claim 1 wherein said VH and VL regions have the amino acid sequences of amino acid residues 20 to 143 in SEQ ID NO:2 and of amino acid residues 21 to 127 in SEQ ID NO:4, respectively.

4. The antibody of claim 1 wherein the amino acid sequence of the H chain constant region of said antibody is that of SEQ ID NO:6 and the amino acid sequence of the L chain constant region of said antibody is that of SEQ ID NO:8 or of SEQ ID NO:10.

5. A gene fragment coding for a heavy chain variable region (VH) or a part thereof of an antibody which specifically reacts with feline herpes virus-1 (FHV-1) in which the nucleotide sequence coding for complementarity determining region 3 (CDR3) comprises a nucleotide sequence coding for the amino acid sequence Asp Gly Ala Trp Phe Pro Phe corresponding to amino acid residues 126 to 132 of SEQ ID NO:2.

6. The gene fragment of claim 5 wherein the nucleotide sequences coding for CDRs 1 to 3 are nucleotide sequences coding for the following amino acid sequences, respectively: SEQ ID NO:2. amino acids 71 to 86 of SEQ ID NO:2. acids 119 to 132 of SEQ ID NO:2.

7. The gene fragment of claim 5 wherein the nucleotide sequence coding for VH of the antibody is a nucleotide sequence coding for the amino acid sequence of SEQ ID NO:2.

8. The gene fragment of claim 5 wherein the nucleotide sequence coding for VH of the antibody is the corresponding to nucleotides 21 to 449 of SEQ ID NO:1.

9. A gene fragment coding for a light chain variable region (VL) of an antibody wherein the nucleotide sequences coding for CDRs 1 to 3 are nucleotide sequences coding for the following amino acid sequences, respectively: 54 of SEQ ID NO:4; NO:4 and of SEQ ID NO:4.

10. The gene fragment of claim 9 wherein the nucleotide sequence coding for VL of the antibody is a nucleotide sequence coding for the amino acid sequence of SEQ ID NO:4.

11. The gene fragment of claim 9 wherein the nucleotide sequence coding for VL of the antibody is the nucleotide corresponding to nucleotides 23 to 403 of SEQ ID NO:3.

12. A recombinant gene fragment coding for heavy (H) chain of a feline chimeric antibody which specifically reacts with feline herpes virus-1 (FHV-1), said gene fragment comprising the gene fragment of claim 5 to the downstream (3' site) of which a gene fragment coding for H chain constant region of a feline antibody is bound.

13. The recombinant gene fragment of claim 12 wherein said gene fragment coding for H chain constant region of a feline antibody has a nucleotide sequence coding for the amino acid sequence of SEQ ID NO:6.

14. A recombinant gene fragment coding for light (L) chain of a feline chimeric antibody which specifically reacts with feline herpes virus-1 (FHV-1), said gene fragment comprising the gene fragment of claim 9 to the downstream (3' site) of which a gene fragment coding for .kappa. chain constant region of a feline antibody is bound.

15. The recombinant gene fragment of claim 14 wherein said gene fragment coding for .kappa. chain constant region of a feline antibody has a nucleotide sequence coding for the amino acid sequence of SEQ ID NO:8.

16. A recombinant gene fragment coding for L chain of a feline chimeric antibody which specifically reacts with feline herpes virus-1 (FHV-1), said gene fragment comprising the gene fragment of claim 9 to the downstream (3' site) of which a gene fragment coding for .lambda. chain constant region of a feline antibody is bound.

17. The recombinant gene fragment of claim 16 wherein said gene fragment coding for .lambda. chain constant region of a feline antibody has a nucleotide sequence coding for the amino acid sequence of SEQ ID NO:10.

18. A method of treating FHV-1-infected cats, comprising the step of administering a pharmaceutical composition, comprising the felinized chimeric antibody according to claim 2 and a pharmaceutically acceptable excipient, to a cat in need thereof.